3 research outputs found
Cheminformatics Modeling of Adverse Drug Responses by Clinically Relevant Mutants of Human Androgen Receptor
The
human androgen receptor (AR) is a ligand-activated transcription factor
that plays a pivotal role in the development and progression of prostate
cancer (PCa). Many forms of castration-resistant prostate cancer (CRPC)
still rely on the AR for survival. Currently used antiandrogens face
clinical limitations as drug resistance develops in patients over
time since they all target the mutation-prone androgen binding site
(ABS), where gain-of-function mutations eventually convert antagonists
into agonists. With a significant number of reported distinct mutations
located across the ABS, it is imperative to develop a prognostic platform
which would equip clinicians with prior knowledge and actionable strategies
if cases of previously unreported AR mutations are encountered. The
goal of this study is to develop a theoretical approach that can predict
such previously unreported AR mutants in response to current treatment
options for PCa. The expected drug response by these mutants has been
modeled using cheminformatics methodology. The corresponding QSAR
pipeline has been created, which extracts key protein–ligand
interactions and quantifies them by 4D molecular descriptors. The
developed models reported with an accuracy reaching 90% and enable
prediction of activation of AR mutants by its native ligand as well
as assess whether known antiandrogens will act on them as agonists
or antagonists. As a result, a previously uncharacterized mutant,
T878G, has been predicted to be activated by the latest antiandrogen
enzalutamide, and the corresponding experimental evaluation confirmed
this prediction. Overall, the developed cheminformatics pipeline provides
useful insights toward understanding the changing genomic landscape
of advanced PCa
Additional file 3: Figure S2. of Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients
Activation of wild-type AR by dihydrotestosterone (DHT), progesterone, estradiol, and hydrocortisone. The graphs represent the average ± SEM of three independent experiments with four replicates each. (TIF 252 kb
Additional file 1: Table S1. of Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients
The results of the validation of a subset of detected mutations on MiSeq, Illumina. The run was designed to test 23 mutations in 11 cfDNA samples (both amplified and non-amplified). WGA samples are marked with *, n/a – sample not sequenced on MiSeq. Only two calls were not supported on MiSeq. S889G call in VC-012-t1 unamplified cfDNA was not detected on original 454 run, or on MiSeq resequencing. (DOCX 23 kb